Literature DB >> 16433891

Muscle symptoms associated with statins: a series of twenty patients.

Kari Soininen1, Mikko Niemi, Esa Kilkki, Timo Strandberg, Kari T Kivistö.   

Abstract

The aim of this study was to examine the clinical profile of statin-induced myalgia in patients with no apparent predisposing factors. Patients who reported muscle complaints that limited daily functioning during statin use were prospectively identified among the patients of Kuusankoski District Hospital and its catchment area, a population of about 100,000, between January 2003 and July 2004. Twenty patients in whom the muscle complaints were probably attributable to the use of a statin were included in this series. There were no cases of severe myopathy or rhabdomyolysis, and the highest creatine kinase value observed was only about 1900 U/l. Of the 18 patients that were evaluable for creatine kinase level, 5 (28%) did not exhibit elevation of creatine kinase and 6 (33%) showed a minor increase only. Following discontinuation of the statin, resolution of symptoms and normalisation of creatine kinase occurred in 11 of the 13 patients with elevated creatine kinase value as well as muscle complaints. Statins may cause clinically important muscle symptoms without inducing a marked creatine kinase elevation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16433891     DOI: 10.1111/j.1742-7843.2006.pto_193.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  10 in total

1.  A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design.

Authors:  Paul D Thompson; Beth A Parker; Priscilla M Clarkson; Linda S Pescatello; C Michael White; Adam S Grimaldi; Benjamin D Levine; Ronald G Haller; Eric P Hoffman
Journal:  Prev Cardiol       Date:  2010

Review 2.  Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.

Authors:  Andrew L Mammen
Journal:  Nat Rev Neurol       Date:  2011-06-08       Impact factor: 42.937

3.  Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy.

Authors:  Andrew L Mammen; Tae Chung; Lisa Christopher-Stine; Paul Rosen; Antony Rosen; Kimberly R Doering; Livia A Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2011-03

Review 4.  Update on toxic myopathies.

Authors:  F L Mastaglia; M Needham
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

5.  Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance.

Authors:  Kevin D Ballard; Beth A Parker; Jeffrey A Capizzi; Adam S Grimaldi; Priscilla M Clarkson; Stephanie M Cole; Justin Keadle; Stuart Chipkin; Linda S Pescatello; Kathleen Simpson; C Michael White; Paul D Thompson
Journal:  Atherosclerosis       Date:  2013-07-13       Impact factor: 5.162

Review 6.  Statin myopathy.

Authors:  Kristofer A Radcliffe; William W Campbell
Journal:  Curr Neurol Neurosci Rep       Date:  2008-01       Impact factor: 5.081

Review 7.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

8.  Atorvastatin for unruptured intracranial vertebrobasilar dissecting aneurysm (ATREAT-VBD): protocol for a randomised, double-blind, blank-controlled trial.

Authors:  Mirzat Turhon; Huibin Kang; Jiliang Huang; Mengxing Li; Jian Liu; Ying Zhang; Kun Wang; Xinjian Yang; Yisen Zhang
Journal:  BMJ Open       Date:  2022-04-28       Impact factor: 3.006

9.  Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006.

Authors:  Mariam Molokhia; Paul McKeigue; Vasa Curcin; Azeem Majeed
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

10.  Effect of ATorvastatin On Chronic subdural Hematoma (ATOCH): a study protocol for a randomized controlled trial.

Authors:  Rongcai Jiang; Dong Wang; Wai Sang Poon; Yi Cheng Lu; Xin Gang Li; Shi Guang Zhao; Ren Zhi Wang; Chao You; Xian Rui Yuan; Jian Min Zhang; Hua Feng; Zhou Fei; Xin Guang Yu; Yuan Li Zhao; Jin Hu; De Zhi Kang; Ru Tong Yu; Guo Dong Gao; Xi De Zhu; Tao Sun; Jie He Hao; Xian Zhi Liu; Ning Su; Shu Yuan Yue; Jian Ning Zhang
Journal:  Trials       Date:  2015-11-18       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.